Participants 275 patients aged 18-65 years with irritable bowel syndrome.
Interventions 12 weeks of treatment with 10 g psyllium (n=85), 10 g bran (n=97), or 10 g placebo (rice flour) (n=93).
Main outcome measures The primary end point was adequate symptom relief during at least two weeks in the previous month, analysed after one, two, and three months of treatment to assess both short term and sustained effectiveness. Secondary end points included irritable bowel syndrome symptom severity score, severity of abdominal pain, and irritable bowel syndrome quality of life scale.
Results The proportion of responders was significantly greater in the psyllium group than in the placebo group during the first month (57% v 35%; relative risk 1.60,95% confidence interval 1.13 to 2.26) and the second month of treatment (59% v41%; 1.44,1.02 to 2.06). Bran was more effective than placebo during the third month of treatment only (57% v32%; 1.70,1.12 to 2.57), but this was not statistically significant in the worst case analysis (1.45,0.97 to 2.16). After three months of treatment, symptom severity in the psyllium group was reduced by 90 points, compared with 49 points in the placebo group (P=0.03) and 58 points in the bran group (P=0.61 versus placebo). No differences were found with respect to quality of life. Fifty four (64%) of the patients allocated to psyllium, 54 (56%) in the bran group, and 56 (60%) in the placebo group completed the three month treatment period. Early dropout was most common in the bran group; the main reason was that the symptoms of irritable bowel syndrome worsened. Patients were randomly allocated to a 12 week treat ment regimen with 10 g psyllium (soluble fibre), 10 g bran (insoluble fibre), or placebo (rice flour) in two daily dosages. The average intake of dietary fibre in an adult Dutch population aged 25-65 years is estimated to be 24.0 (SD 6.9) g/day. An addition of 10 g fibre to the diet (total dietary fibre content 30-40 g) is usually considered adequate.9 The study was blinded at three levels (patient, doctor, and research personnel), but the practice nurse was aware of the treatment allocated.
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Outcomes measures
We used the adequate relief question ("Did you have adequate relief of irritable bowel syndrome related abdominal pain or discomfort in the past week?") as the primary outcome.1011 We assessed the primary out come after one, two, and three months of treatment and defined responders as those patients who reported adequate relief of symptoms during at least two out of the previous four weeks. 12 Patients were asked to keep a weekly diary during the 12 weeks of treatment and to measure adherence to treatment. We calculated the primary outcome from weekly assessments.
Secondary outcome measurements included severity of symptoms of irritable bowel syndrome, severity of abdominal pain, and quality of life. Severity of symptoms was assessed with the irritable bowel syndrome symptom severity score. The severity of abdominal pain was meas ured by means of the first question of this score.13 Disease specific quality of life was monitored with the irritable bowel syndrome quality of life scale.14 Fibre intake was monitored every month during the trial with a food fre quency questionnaire. The secondary outcomes were recorded during one, two, and three months.
Data analysis
Statistical analyses were based on the intention to treat principle. We calculated the proportion of responders in the three groups and compared them at one, two, and three months. Relative risks and risk differences compared with placebo were calculated. Changes in the secondary outcomes at one, two, and three months after the baseline measurements were also compared. To correct for possible differences in relevant baseline characteristics between the three groups, we did multiple logistic regression analyses. 
RESULTS
Participants
A total of 296 patients agreed to participate in the trial.
In total, 275 patients attended the baseline visit and were randomised; 85 were allocated to psyllium, 97 to bran, and 93 to placebo. More than half (56%) of the patients had constipation predominant irritable bowel syndrome.
The mean intake of dietary fibre before participation was 26.9 (SD 11.8) g/day, and patients used on average 2.4 (1.0) 1/day of fluids. At baseline, patients allocated to psyllium reported less severe abdominal pain associated with irritable bowel syndrome than did those in the bran and placebo groups.
Two hundred and thirty four (85%) patients attended the second visit at one month, 195 (71%) attended the visit at two months, and 164 (60%) attended the final visit at the end of the three month treatment period. In total, 111 (40%) patients were lost to follow-up during the treatment period: 31 (36%) in the psyllium group, 43 (44%) in the bran group, and 37 (40%) in the placebo group. Reasons given were non-medical (n= 15), presumed lack of benefit (n= 10), symptom free (n=2), and intolerance of trial treat ment (n=34; 7 patients allocated to psyllium, 18 patients allocated to bran, and 9 patients allocated to placebo).
Primary outcome
Rates of response were significandy higher with psyllium than with placebo during the first month of treatment (45/79 (57%) v 27/78 (35%); relative risk 1.60,95% con fidence interval 1.13 to 2.26), with a risk difference of 22% (95% confidence interval 7% to 38%). The number needed to treat was four. We saw a similar positive effect Adjustment for baseline symptom severity in the multivariate logistic regression analysis only increased the observed beneficial effect?in the first month of treat ment the relative risk for adequate relief in the psyllium group versus the placebo group was 2.70 (1.33 to 5.46). In the worst case analysis (considering patients lost to follow-up as non-responders), psyllium remained more effective than placebo during the first two months of treatment, but bran was no longer superior to placebo during the third month (1.45,0.97 to 2.16).
Secondary outcomes
The reduction in severity of symptoms in the psyllium group was higher than that in the placebo group, with a significant mean reduction of 90 versus 49 points (P=0.03) only after three months of treatment, whereas the change in severity of symptoms in the bran group was compa rable to that in the placebo group. We found no signifi cant differences between the three groups with respect to changes in the severity of abdominal pain related to irritable bowel syndrome or in quality of life (table 2) . 
DISCUSSION
In this randomised trial in primary care patients with irritable bowel syndrome, psyllium resulted in a signifi candy greater proportion of patients reporting adequate relief of symptoms compared with placebo supplemen tation. Patients receiving psyllium also reported a sig nificant reduction in severity of symptoms of irritable bowel syndrome. We found no differences between the treatment groups in abdominal pain or health related quality of life. Bran showed no clinically relevant benefit, and many patients seemed not to tolerate bran.
Potential limitations
The selection process may have affected the general isability of the results. A detailed comparison of ran domised patients with eligible but non-randomised patients with irritable bowel syndrome (n=371) and non-eligible patients with irritable bowel syndrome (n=724) is reported elsewhere and showed that ran domised patients had a higher intensity of abdominal pain, a higher consultation rate, and a longer history of irritable bowel syndrome. 15 Successful blinding of dietary interventions in research is difficult to achieve, but we took maximum precautions to guarantee that the treatments looked identical. Clinical staff involved were kept blinded to treatment allocation.
However, in retrospect approximately three quarters of patients correctly guessed which treatment they were given. We have no clear explanation for this.
Forty per cent of the patients in this study stopped participation before the final visit. The main reason was that they felt worse when taking the fibre supplement. Although this dropout rate is considerable, it is compa rable to that in other trials of this nature.1648 Obviously, a high dropout rate is going to contribute negatively to the overall result of the study. Although this "worst case scenario" is the most appropriate way of analysing the effectiveness of treatment, it may underestimate the true effectiveness of fibre treatment.11
The dropout rate was highest among those patients randomised to bran. This was mainly attributed to wors ening of symptoms of irritable bowel syndrome. This has also been reported in secondary care.1920
Implications of findings
The results of this large scale trial in primary care support the addition of soluble fibre, such as psyllium, but not bran as an effective first treatment approach in the clinical management of patients with irritable bowel syndrome.
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